National Clinical Research Center for Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai, China.
J Diabetes. 2019 Sep;11(9):752-760. doi: 10.1111/1753-0407.12904. Epub 2019 Feb 18.
Serum apolipoprotein (apo) B has been associated with an increased risk of atherosclerotic cardiovascular diseases. However, findings on the association between apoB and the risk of metabolic syndrome (MetS) are inconsistent. The purpose of this study was to investigate the association between serum apoB and MetS risk in Chinese population.
A baseline survey was conducted in a population-based cohort of 10 340 adults aged ≥40 years in Shanghai, China, in 2010. A follow-up visit was conducted to assess incident diabetes in 2015.
At baseline, 2794 of 10 340 participants (27.02%) had MetS. Serum apoB was significantly associated with an increased risk of prevalent MetS. Multivariable-adjusted odds ratios and 95% confidence intervals (CIs) for quintiles 2-5 compared with quintile 1 (reference) were 1.29 (1.02-1.63), 1.47 (1.18-1.84), 1.32 (1.06-1.65), and 2.02 (1.61-2.51), respectively (P < 0.05). During an average of 5.1 years follow-up, 4627 individuals without MetS at baseline showed a significant association between apoB and the risk of incident MetS. Multivariable-adjusted risk ratios (95% CIs) for subjects in apoB quintiles 2-5 compared with the reference were 1.43 (1.13-1.82), 1.57 (1.25-1.98), 1.74 (1.38-2.18), and 2.07 (1.66-2.58), respectively (P < 0.05). Stratified analysis suggested that the above association was much stronger among normal weight individuals than in those who were overweight or obese.
These cross-sectional and prospective studies provide evidence that serum apoB is associated with existing MetS and is a possible predictor of the risk of MetS, especially among normal weight individuals.
血清载脂蛋白(apo)B 与动脉粥样硬化性心血管疾病风险增加有关。然而,apoB 与代谢综合征(MetS)风险之间的关联的研究结果并不一致。本研究旨在探讨中国人群血清 apoB 与 MetS 风险之间的关系。
2010 年在中国上海进行了一项基于人群的、年龄在 40 岁及以上的 10340 名成年人的基线调查。在 2015 年进行了随访,以评估糖尿病的发病情况。
在基线时,10340 名参与者中有 2794 人(27.02%)患有 MetS。血清 apoB 与现患 MetS 的风险显著相关。与 quintile 1(参考)相比,quintile 2-5 的多变量调整优势比(95%置信区间)分别为 1.29(1.02-1.63)、1.47(1.18-1.84)、1.32(1.06-1.65)和 2.02(1.61-2.51)(P < 0.05)。在平均 5.1 年的随访期间,基线时无 MetS 的 4627 名个体中,apoB 与 MetS 发病风险之间存在显著关联。与 quintile 1 相比,quintile 2-5 的多变量调整风险比(95%置信区间)分别为 1.43(1.13-1.82)、1.57(1.25-1.98)、1.74(1.38-2.18)和 2.07(1.66-2.58)(P < 0.05)。分层分析表明,在体重正常的个体中,这种关联比超重或肥胖的个体更强。
这些横断面和前瞻性研究提供了证据,表明血清 apoB 与现有的 MetS 相关,并且可能是 MetS 风险的预测因子,尤其是在体重正常的个体中。